U.S. markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.20 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.50 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.98
    +0.68 (+0.93%)
     
  • Gold

    1,750.60
    +0.80 (+0.05%)
     
  • Silver

    22.37
    -0.27 (-1.20%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3681
    -0.0040 (-0.29%)
     
  • USD/JPY

    110.6850
    +0.3840 (+0.35%)
     
  • BTC-USD

    43,244.29
    +543.77 (+1.27%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know

·3 min read

GlaxoSmithKline (GSK) closed at $41.43 in the latest trading session, marking a +0.78% move from the prior day. This change outpaced the S&P 500's 0.28% gain on the day.

Prior to today's trading, shares of the drug developer had gained 1.51% over the past month. This has lagged the Medical sector's gain of 2.77% and the S&P 500's gain of 3.07% in that time.

Investors will be hoping for strength from GSK as it approaches its next earnings release. The company is expected to report EPS of $0.79, down 14.13% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.01 billion, up 7.55% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $2.77 per share and revenue of $45.63 billion, which would represent changes of -7.05% and +4.16%, respectively, from the prior year.

Any recent changes to analyst estimates for GSK should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.97% higher within the past month. GSK is holding a Zacks Rank of #3 (Hold) right now.

Digging into valuation, GSK currently has a Forward P/E ratio of 14.82. For comparison, its industry has an average Forward P/E of 14.78, which means GSK is trading at a premium to the group.

Investors should also note that GSK has a PEG ratio of 2.17 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.21 based on yesterday's closing prices.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 119, which puts it in the top 47% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow GSK in the coming trading sessions, be sure to utilize Zacks.com.


More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.

Click here for the 4 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.